Arena Pharmaceuticals Inc. (ARNA) Moves Lower on Volume Spike for March 15

Equities Staff  |

Arena Pharmaceuticals Inc. (ARNA) traded on unusually high volume on Mar. 15, as the stock lost 8.38% to close at $33.01. On the day, Arena Pharmaceuticals Inc. saw 2.02 million shares trade hands on 14,671 trades. Considering that the stock averages only a daily volume of 571,073 shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $44.50 and $11.30 over the last 52-weeks, its 50-day SMA is now $39.01, and its 200-day SMA $27.58. Arena Pharmaceuticals Inc. has a P/B ratio of 5.93.

Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.

Headquartered in San Diego, CA, Arena Pharmaceuticals Inc. has 106 employees and is currently under the leadership of CEO .

For a complete fundamental analysis analysis of Arena Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for ARNA.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

To get more information on Arena Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ARNA’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Online Sales Declined on Black Friday and Cyber Monday for First Time
Profiting From Energy Efficient Cryptocurrency Mining
Is AI Ready for Prime Time: Jeff Kagan
Stocks Close Broadly Lower as Powell Signals Faster Tapering by Fed
UK Regulator Rules Facebook Must Sell Giphy
US Bank Profits Slip 1.2% in Q3
Omicron Variant Reached Europe Earlier Than Previously Thought
Vaccine Stocks Soar Amid Omicron-Related Volatility

Market Movers

Sponsored Financial Content